Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission
In this medfyle
Residual disease (RD) is the main prognostic factor in acute lymphoblastic leukemia (ALL) and is widely used to define post-remission treatment in children and adults. ER should be evaluated sequentially throughout the treatment of ALL, where it has always demonstrated predictive power for relapse. However, the moments with greatest decision-making capacity are after induction and consolidation.
About this Medfyle
This Medfyle is provided as a service to healthcare professionals. It has been created from content originally published in Blood, the American Society of Hematology's official journal.
Original article:
Jabbour E, Haddad FG, Short NJ, Senapati J, Jain N, Sasaki K, Jorgensen J, Wang SA, Alvarado Y, Wang X, DiNardo C, Masarova L, Kadia T, Garris RS, Ravandi F, Kantarjian H. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood. 2024 Feb 1;143(5):417-421. doi: 10.1182/blood.2023022330. PMID: 37879077.
Copyright© 2024 American Society of Hematology. All rights reserved.
